TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05098743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medisafe smartphone mobile application
Description: The medication adherence smartphone mobile application (app) will provide reminders to take individual patient medications and offers medication information and a social support feature.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed medication list
Description: Patients will receive a printed out medication list from their electronic medical record.
Study: NCT05760261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: GSK3882347 will be administered.
Study: NCT06141473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: SAR441344 Solution for IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Aubagio oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine
Description: oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activated charcoal
Description: oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
Study: NCT06136832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Education
Description: Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia
Study: NCT05753449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst-type DBS electrical stimulation programming
Description: Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care DBS programming
Description: Standard of care DBS stimulation programming
Study: NCT05038566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pointdexter
Description: i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
Study: NCT05597878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Given after surgery 5 mg every 6 hours as needed for severe pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Given before and during surgery 1.5 mg/kg intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
Study: NCT04779593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIMS2_SF questionnaire
Description: At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WOMAC questionnaire
Description: At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
Study: NCT04873622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health
Description: RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
Study: NCT05909293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venclexta 100 MG Oral Tablet
Description: When there is a deficiency of neutrophils, G-CSF treatment may be necessary. The treatment is continued until the absolute neutrophil count (ANC) reaches either \>0.5×109/L and remains at that level for 3 consecutive days, or \>2×109/L. The purpose of G-CSF therapy in this context is to stimulate the production of neutrophils and restore their levels to a sufficient and stable range. This helps to strengthen the immune system and reduce the risk of infections associated with low neutrophil counts.~When experiencing Grade 3-4 thrombocytopenia, subcutaneous injection of IL-11 can be administered as a treatment.~When symptoms of infection occur, aggressive antimicrobial therapy and other supportive treatments should be administered.~All blood products should undergo irradiation when transfused, and all blood products must be filtered before infusion.~If gastrointestinal adverse reactions occur, antiemetic medications can be administered to alleviate symptoms.
Study: NCT06478823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stools donation
Description: Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.~Donors will be followed from their selection until 6 months after their last valid stool donation.
Study: NCT04779593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WOMAC questionnaire
Description: At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
Study: NCT05491343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MedroxyPROGESTERone Injection [Depo-Provera]
Description: The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Other
Description: Follow up using US
Study: NCT06550830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV24 formulation 1
Description: One dose of Sinovac PCV24 formulation 1(0.5mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV24 formulation 2
Description: One dose of Sinovac PCV24 formulation 2(0.5mL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13®
Description: One dose of PCV13 manufactured by Pfizer
Study: NCT06104917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Maolactin
Description: Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
Study: NCT04779593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQ-5D-5L questionnaire
Description: At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L questionnaire
Description: At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Complete blood count
Description: Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
Study: NCT06104917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Maolactin
Description: Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Once daily dose of 2 capsules
Study: NCT05625425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LabyrinthVR software
Description: Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Games software
Description: Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labyrinth Tablet software
Description: Tablet computer playing Labyrinth spatial wayfinding game in 2.5D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labyrinth VR wireless
Description: Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
Study: NCT04632641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES
Description: The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Figure 8 Suture - LARGE-BORE PROCEDURES
Description: A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
Study: NCT05432115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracyclin
Description: Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracyclin
Description: Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
Study: NCT06780761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation training
Description: The author further demonstrated taking body temperature, heart rate and its characteristics, respiratory rate and saturation, blood pressure and pain assessment in line with previously created cases on the NOELLE® Maternal Birthing Simulator with Advanced Resuscitation Neonatal M-W45111 to the students deployed in the intervention group. Furthermore the students were allowed to work individually on the infant simulator, their questions were answered and feedback was given to them. Students were also offered free time to work on the infant simulator. One week after the training, before proceeding with the clinical practice, the students were individually assessed on measuring the vital signs by 2 different observers and were administered the post-tests.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical training
Description: Before proceeding with the clinical practice, the students deployed in the control group were trained on how to measure the five vital signs, which tools to use and why, and normal and abnormal vital sign values by demonstration and explaining on a pediatric nursing manikin. Then, volunteering students were given the opportunity to develop their vital sign measurement skills on a pediatric nursing manikin and feedback was provided to them. One week after the training, all students were individually assessed on measuring the vital signs by 2 different independent observers on the simulator neonatal used in the intervention group and they were administered the post-tests.
Study: NCT06781203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally delivered CBTI (eCBTI)
Description: Based on the existing consensus concerning non-pharmacological treatment of insomnia, Hvil® includes the following treatment components: sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy. Intervention duration is approximately six to nine weeks.
Study: NCT06781905

Intervention type: OTHER
Intervention: Assessments of neuropsychiatric, neurocognitive and psychosocial alterations
Description: Assessments will be conducted over two consecutive days. The first day will focus on the evaluation of neuropsychiatric and neurocognitive alterations. A comprehensive assessment involving various tools (clinical examination, individual interview, psychometric tests, standardized scales) will be carried out by a psychiatrist, a neuropsychologist, and a neurologist. The second day will be dedicated to psychosocial assessments by a team of social psychologists using a comprehensive qualitative and quantitative approach to quality of life. Quality of life will be understood as a subjective appreciation of the individual's place in their existence and three main dimensions will be explored: daily life management, social relationships, and self-image and self-esteem. The collected data will be subjected to a reflexive thematic analysis. The qualitative exploration of quality of life will be complemented by a quantitative assessment using a standardized tool (EORTC QLQ LC13).
Study: NCT06781515

Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral and BM blood sample
Description: Peripheral and BM blood samples will be analyzed with the ddPCR method
Study: NCT06109259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1567
Description: One tablet of DWJ1567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC202312
Description: One tablet of DWC202312
Study: NCT04149288

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-polyphenol olive oil
Description: High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-polyphenol olive oil
Description: Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
Study: NCT05709535

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-PSMA-1007
Description: \[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
Study: NCT04912869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
Study: NCT05336266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
Study: NCT05393921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical Botox injection
Description: Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
Study: NCT05053503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sparrow Ascent Therapy System
Description: Transcutaneous auricular neurostimulation (tAN)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sparrow Ascent Therapy System
Description: Transcutaneous auricular neurostimulation (tAN)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sparrow Ascent Therapy System
Description: Transcutaneous auricular neurostimulation (tAN)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lofexidine
Description: Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone
Description: Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-release injectable naltrexone
Description: Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
Study: NCT05660980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once daily CAB tablet + RPV tablet
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once daily CAB tablet + RPV tablet
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting CAB injectable + long acting RPV injectable
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting CAB injectable + long acting RPV injectable
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting CAB injectable + long acting RPV injectable
Description: Injectable
Study: NCT05586191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation at home
Description: Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Observation therapy at hospital
Description: Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects.